The Immutep (ASX:IMM) share price is up 6% today

Immutep has received all the approvals it needs to begin its latest trial in the United States.

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Immutep Ltd (ASX: IMM) are soaring today following news of its latest drug trial. Currently, the Immutep share price is trading at 56 cents, 5.6% higher than its previous close.

The biotechnology company has received approval from both the United States Food and Drug Association (FDA) and Institutional Review Board (IRB) to begin the trial.

Let's take a closer look at today's news from Immutep.

New trial gets US approval

Immutep can now begin a phase IIb trial, combining its lead product candidate, eftilagimod alpha (efti), with MSD's immunotherapy treatment, Keytruda (pembrolizumab).

The company — which develops immunotherapy treatments for cancer and autoimmune disease — is focussing on Efti, an antigen-presenting cell activator.

Immutep advised that the TACTI-003 trial will be a randomised, controlled clinical study. It aims to find if efti and pembrolizumab can be combined to treat head and neck squamous cell carcinoma (HNSCC).

Immutep plans for the trial to involve around 154 patients. It hopes it will take place in Australia and Europe, as well as the United States.

The trial is pending approval from authorities and ethics committees in Australia and Europe.

Immutep expects patient recruitment for the trial to begin in the United States in the current quarter, with Australian and European sites to follow.

Commentary from management

Immutep chief scientific officer and chief medical officer Frédéric Triebel said:

We are delighted to start our new TACTI-003 trial in 1st line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab monotherapy.

Results we reported from this therapeutic combination earlier in June at [the American Society of Clinical Oncology] in the 2nd line setting were robust, with sustained and durable responses. We look forward to deepening these results with a larger group of 1 st line HNSCC patients in TACTI-003.

Immutep share price snapshot

2021 has been a good year so far for the Immutep share price on the ASX.

It's currently 34% higher than it was at the start of the year, and has gained 232% since this time last year.

The company has a market capitalisation of around $407 million, with approximately 648 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »